Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.37 |
| ▸ | CDK9 | P50750 | 2/20 | 0.37 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.37 |
| ▸ | ESRRA | P11474 | 1/20 | 0.36 |
| ▸ | SRC | P12931 | 5/20 | 0.35 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.34 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.34 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.34 |
| ▸ | FLT3 | P36888 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4241149 | 1.00 | KDM4E (0.38) | KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4241829 | 0.90 | CDK9 (0.40) | HPGDSMN1; SMN2ALOX5CDK9ESRRA | |
| SCHEMBL4241832 | 0.90 | CDK9 (0.40) | HPGDSMN1; SMN2ALOX5CDK9ESRRA | |
| SCHEMBL4244023 | 0.86 | ACVR1 (0.41) | KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4244021 | 0.86 | ACVR1 (0.41) | KDM4EHSD17B10HPGDALDH1A1SMN1; SMN2 | |
| SCHEMBL4242647 | 0.86 | ALOX5 (0.39) | HPGDALOX5CDK9CISD1ESRRA | |
| SCHEMBL4242645 | 0.86 | ALOX5 (0.39) | HPGDALOX5CDK9CISD1ESRRA | |
| SCHEMBL4241180 | 0.83 | HDAC1 (0.41) | ALDH1A1CDK9CISD1ESRRASRC | |
| SCHEMBL4241173 | 0.83 | HDAC1 (0.41) | ALDH1A1CDK9CISD1ESRRASRC | |
| SCHEMBL4244069 | 0.83 | CISD1 (0.42) | ALOX5CISD1ENPP2HDAC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | claimed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | claimed |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | SMITHKLINE BEECHAM CORPORATION | 2009-02-19 | — | — | US | disclosed |
| US-20070249599-A1 | Novel Chemical Compounds | DUFFY KEVIN J | 2007-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070249599-A1 | Novel Chemical Compounds | HIPK3, HIPK1, HIPK4 | KDM4E 2565/4885HSD17B10 920/4885HPGD 3707/4885 |
| US-20090048252-A1 | THIAZOLONES FOR USE AS PI3 KINASE INHIBITORS | PIK3CA, BTK, PI4KA | KDM4E 3686/4885HSD17B10 3245/4885HPGD 3782/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.